Why Integra LifeSciences (IART) Shares Are Trading Lower Today
Update: 2025-11-03
Description
Investors watched as Integra LifeSciences' stock plummeted by nearly six percent following a disappointing third-quarter earnings report. The medical device maker's sales fell short of expectations due to supply interruptions, leading to lower profit forecasts and a Hold rating from Truist Securities with a price estimate of $13, down from $15. Citigroup maintained a sell recommendation and lowered their target to $11. Despite the latest dip, the stock has lost over half its value since the start of the year, leaving investors to decide if this is a buying opportunity or another bump in a rough road.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
